# 2025年11月5日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 左乙拉西坦与丙戊酸治疗卒中后癫痫发作的有效性：一项基于人群的目标试验模拟研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41183250](https://pubmed.ncbi.nlm.nih.gov/41183250)
**期刊：** Neurology
**PMID：** 41183250
**DOI：** 10.1212/WNL.0000000000214319

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of Levetiracetam vs Valproic Acid for Poststroke Seizure: A Population-Based Study Using a Target Trial Emulation Framework.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Evidence on levetiracetam for poststroke seizures is limited. Understanding whether levetiracetam effectively manages poststroke seizures is important for improving prognosis and preventing further complications in stroke patients. The aim of this study was to assess the risk of seizure rehospitalization between levetiracetam and valproic acid in patients with poststroke seizures.

METHODS: Using data from Taiwan's National Health Insurance Research Database, this observational retrospective cohort study followed the target trial emulation framework to emulate a hypothetical randomized trial estimating the effect of levetiracetam for poststroke seizure management. Eligible patients were those who were hospitalized for their first seizure event (index seizure) between January 1, 2012, and December 31, 2020, and were newly prescribed levetiracetam or valproic acid monotherapy before discharge. Patients should have had a stroke-related hospitalization within 2 years before the seizure. Patients prescribed levetiracetam were assigned to the exposure group, whereas those prescribed valproic acid were assigned to the reference group, based on their first prescription after the index seizure. Inverse probability-weighted marginal structural models were used to assess outcomes between levetiracetam and valproic acid, including seizure rehospitalization as the primary outcome. Secondary outcomes included all-cause mortality and a composite of seizure rehospitalization and all-cause mortality. Both baseline and time-varying confounders were adjusted in the models.

RESULTS: The final sample included 740 levetiracetam users (48.5%) and 786 valproic acid users, with a mean age of 67.2 years in both groups and a similar proportion of men (59.9% for levetiracetam; 61.3% for valproic acid). In the primary outcome analysis, levetiracetam use was associated with a lower risk of seizure rehospitalization compared with valproic acid (hazard ratio 0.78; 95% CI 0.64-0.95). In secondary outcome analyses, no significant differences were observed in all-cause mortality or the composite of seizure rehospitalization and all-cause mortality.

DISCUSSION: Levetiracetam was associated with a lower risk of seizure rehospitalization, with no significant difference in the risk of all-cause mortality. These findings support levetiracetam as a potentially suitable treatment option for patients with poststroke seizures. As this study focused on monotherapy, future investigations should further explore combination antiseizure medication regimens involving levetiracetam.

CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that levetiracetam is associated with a lower risk of seizure rehospitalization compared with valproic acid in patients with post-stroke seizures.

**中文摘要译文：**
背景与目的：关于左乙拉西坦用于治疗卒中后癫痫发作的证据有限。了解左乙拉西坦是否能有效控制卒中后癫痫发作，对于改善卒中患者的预后和预防进一步并发症至关重要。本研究旨在评估卒中后癫痫发作患者使用左乙拉西坦与丙戊酸后，因癫痫发作再住院的风险。

方法：本研究是一项观察性回顾性队列研究，利用台湾“全民健康保险研究数据库”的数据，遵循目标试验模拟框架，以模拟一项旨在评估左乙拉西坦在卒中后癫痫发作管理中效果的假设性随机试验。符合条件的患者为在2012年1月1日至2020年12月31日期间因首次癫痫发作事件（指标性癫痫发作）住院，并在出院前首次接受左乙拉西坦或丙戊酸单药治疗的患者。患者在癫痫发作前2年内应有卒中相关的住院史。根据指标性癫痫发作后的首次处方，接受左乙拉西坦治疗的患者被分配到暴露组，而接受丙戊酸治疗的患者则被分配到参照组。研究采用逆概率加权的边际结构模型来评估左乙拉西坦与丙戊酸的治疗结局，其中癫痫再住院为主要结局。次要结局包括全因死亡率以及癫痫再住院和全因死亡率的复合结局。模型中对基线和时变混杂因素均进行了校正。

结果：最终样本包括740名左乙拉西坦使用者（48.5%）和786名丙戊酸使用者，两组平均年龄均为67.2岁，男性比例相似（左乙拉西坦组为59.9%；丙戊酸组为61.3%）。在主要结局分析中，与丙戊酸相比，使用左乙拉西坦与更低的癫痫再住院风险相关（风险比 0.78；95% CI 0.64-0.95）。在次要结局分析中，全因死亡率或癫痫再住院与全因死亡率的复合结局方面未观察到显著差异。

讨论：使用左乙拉西坦与更低的癫痫再住院风险相关，而在全因死亡率风险方面无显著差异。这些发现支持左乙拉西坦作为卒中后癫痫发作患者的一种潜在的合适治疗选择。由于本研究聚焦于单药治疗，未来的研究应进一步探索包含左乙拉西坦的联合抗癫痫药物治疗方案。

证据分级：本研究提供了II级证据，表明在卒中后癫痫发作患者中，与丙戊酸相比，左乙拉西坦与更低的癫痫再住院风险相关。

### 第二部分 AI 大师评价

本研究创新性地采用目标试验模拟框架，基于大规模人群数据，旨在比较左乙拉西坦与丙戊酸在预防卒中后癫痫复发中的临床效果。研究明确指出，与丙戊酸相比，左乙拉西坦能显著降低患者因癫痫再次住院的风险，且未增加全因死亡率。该发现为临床医生在卒中后癫痫的药物选择上提供了强有力的II级证据，尤其是在真实世界场景下。此研究不仅具有重要的临床指导价值，其精巧的研究设计也为利用观察性数据进行高质量因果推断提供了范例。

---

速递结束，祝您工作愉快！